Study S002064

Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04982575
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 92
Start: 2021-08-02
Primary completion: 2022-07-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide 2.4 mg; DRUG:Cagrilintide 2.4 mg; DRUG:Placebo (semaglutide); DRUG:Placebo (cagrilintide)
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) [Week 0, Week 32]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008618	Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Frias JP, Lancet (London, England)	2023	Randomized trial	PMID 37364590 DOI	cites ClinicalTrials.gov:NCT04982575; registry reference BACKGROUND:37364590
R0037265	53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes Juan P. Frías, Diabetes	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04982575
R0051922	54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM Chantal Mathieu, Diabetes	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04982575